Microdosing GLP-1 for Autoimmune Conditions According to a comprehensive systematic review published in 2024, treatment with GLP-1 receptor agonists results in significant reductions in disease severity among patients with psoriasis
Researchers also examined major adverse CV events in patient subgroups on the basis of major adverse CV event rates in the placebo group, the presence or absence of CVD, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age and eGFR
Its ability to slow down food movement through the stomach contributes to a prolonged feeling of fullness, aiding individuals in curbing their appetite and regulating food intake
* Review signs of lithium toxicity with patients starting GLP-1 agonists
Although all three medications main side effects are gastrointestinal issues, there have been several reported cases of suicidal thoughts from patients while taking these medications
While VibraTip is highly effective for screening DPN, its primary role lies in exclusion rather than confirmation of the condition
